Co-Diagnostics CFO reports 134,167 RSUs vested, 40,723 shares sold

Co-Diagnostics, Inc. reported an insider equity transaction by its Chief Financial Officer, Brian L. Brown.

Accepted by SEC EDGAR 11/24/2025 - 05:31 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Co-Diagnostics, Inc. reported an insider equity transaction by its Chief Financial Officer, Brian L. Brown. On 11/23/2025, Brown had 134,167 restricted stock units convert into common stock at an exercise price of $0.00. Following this vesting event, he beneficially owned 599,355 shares of Co-Diagnostics common stock directly.

On the same date, 40,723 shares of common stock were sold at a price of $0.35 per share. The filing explains that these shares were sold solely to cover tax withholding obligations related to the vesting of restricted stock units under the company’s long-term incentive plan and did not represent a discretionary trade by Brown.

Insider Trade Summary

134,167 shares exercised/converted

Exercise 3 txns

Insider Brown Brian Lee

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	134,167	$0.00	$0.00
Grant/Award	Common Stock	134,167	$0.00	$0.00
Disposition	Common Stock	40,723	$0.35	$14K

Holdings After Transaction: Restricted Stock Unit — 337,500 contracts (Direct); Common Stock — 599,355 shares (Direct)

Footnotes (2)

1. F1. Included in 130,000 restricted stock units awarded to the Reporting Person on January 17, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on May 23, 2023. Included in 225,000 restricted stock units awarded to the Reporting Person on May 15, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2023. Included in 225,000 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2024. Included in 225,000 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2025.
2. F2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSU's. This sale is mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Co-Diagnostics (CODX) disclose for the CFO?

The Chief Financial Officer, Brian L. Brown, reported the vesting of 134,167 restricted stock units into common stock on 11/23/2025, along with a related sale of shares to cover taxes.

How many Co-Diagnostics (CODX) shares does the CFO own after this Form 4?

After the reported transactions on 11/23/2025, the CFO beneficially owned 599,355 shares of Co-Diagnostics common stock directly.

What was the purpose of the 40,723 CODX shares sold by the CFO?

The 40,723 shares sold at $0.35 per share were used to cover tax withholding obligations arising from the vesting of restricted stock units, pursuant to a mandated "sell to cover" election under the company’s equity incentive plans.

At what price were the CFO’s Co-Diagnostics shares sold to cover taxes?

The shares sold to satisfy tax withholding obligations were sold at a price of $0.35 per share.

What equity awards are underlying the 134,167 CODX RSUs that vested?

The 134,167 restricted stock units that vested are part of multiple RSU awards granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, with grants made on January 17, 2023, May 15, 2023, April 26, 2024, and August 13, 2025, each vesting in six equal installments every six months from their respective commencement dates.

Does the Form 4 indicate the CFO’s trade was discretionary?

No. The filing states that the sale of 40,723 shares was mandated by the issuer’s election to satisfy tax withholding through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Brian Lee

(Last) (First) (Middle)

C/O CO-DIAGNOSTICS, INC.

2401 S. FOOTHILL DRIVE, SUITE D

(Street)

SALT LAKE CITY UT 84109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Co-Diagnostics, Inc. [ CODX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/23/2025		A		134,167(1)	A	$0.00	640,078	D
Common Stock	11/23/2025		D		40,723(2)	D	$0.35	599,355	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00	11/23/2025		M			134,167	(1)	(1)	Common Stock	471,667	$0.00	337,500	D

Explanation of Responses:

1. Included in 130,000 restricted stock units awarded to the Reporting Person on January 17, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on May 23, 2023. Included in 225,000 restricted stock units awarded to the Reporting Person on May 15, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2023. Included in 225,000 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2024. Included in 225,000 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2025.

2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSU's. This sale is mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Brian L. Brown	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.